The trajectory of companies tied to Viagra's legacy presents a complex investment scenario . While the initial boom generated substantial gains, generic alternatives have significantly diminished revenue. Investing in connected pharmaceutical companies now requires a thorough assessment of intellectual property rights , evolving healthcare changes,